<div id="readability-page-1"><div><p>Wuhan YZY Biopharma (SEHK:2496) has just posted its FY 2025 first half numbers, with revenue of C¥44.4 million and a basic EPS loss of C¥0.30 per share, alongside trailing 12 month revenue of C¥149.3 million and a basic EPS loss of C¥0.40. Over recent periods the company has seen revenue move from C¥2.8 million in 1H 2024 to C¥105.0 million in 2H 2024 and C¥44.4 million in 1H 2025. Over the same intervals, EPS shifted from a loss of C¥0.40 to a loss of C¥0.10 and then a loss of C¥0.30 per share, keeping the focus firmly on how efficiently that revenue is being converted given still negative margins.</p> <p>See our full analysis for Wuhan YZY Biopharma.</p><p>With the headline figures set, the next step is to see how these earnings stack up against the prevailing market narratives around growth potential, risk profile and the timing of any path toward improved profitability.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4a408190-e82a-4e2e-a256-4db0c3c10462/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTAzLTI5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4a408190-e82a-4e2e-a256-4db0c3c10462/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTAzLTI5"/><figcaption>SEHK:2496 Earnings &amp; Revenue History as at Mar 2026</figcaption></figure> <h2>Losses Remain Heavy At C¥58.8 Million</h2> <ul> <li>Net income for 1H 2025 was a loss of C¥58.8 million on C¥44.4 million of revenue, compared with a C¥78.4 million loss on just C¥2.8 million of revenue in 1H 2024. This shows that even with a much larger revenue base the company is still running sizeable losses.</li> <li>What stands out for a bearish view is that trailing 12 month net income is a loss of C¥78.0 million, and basic EPS on this basis is a loss of C¥0.40 per share. This lines up with concerns about ongoing unprofitability even though historical losses have narrowed by an average of 17.6% per year over the past five years.     <ul> <li>Critics highlight that the 1H 2025 loss of C¥58.8 million follows a 2H 2024 loss of C¥19.2 million, so the company is not yet showing a consistent pattern of smaller losses period to period.</li> <li>At the same time, the five year trend of shrinking losses supports the view that operating performance has been improving over a longer window. This is why some investors still focus on progress rather than just the latest half year swing.</li> </ul> </li> </ul> <p>Bears who see these numbers as a warning sign often want to stress test that view against a deeper breakdown of the pipeline, cash needs, and past loss trends before making any big calls on risk. This is where a full bear case can be helpful to read through end to end.<strong>🐻 Wuhan YZY Biopharma Bear Case</strong></p> <h2>P/S Of 4.7x Versus 12.2x Industry</h2> <ul> <li>The current P/S ratio of 4.7x sits well below both the Hong Kong biotechs industry average of 12.2x and the peer average of 10.6x. This means the market is valuing each C¥1 of Wuhan YZY Biopharma's trailing 12 month revenue at a lower multiple than many comparable names.</li> <li>For a bullish angle, fans of the stock argue that this discount lines up with the five year trend of losses narrowing by 17.6% per year and could appeal to investors who focus on companies where the loss profile has been improving while the revenue base has reached C¥149.3 million over the latest 12 month period.     <ul> <li>Supporters point out that the lower 4.7x P/S multiple, alongside trailing 12 month revenue of C¥149.3 million, can be read as the market not fully reflecting the past loss reduction trend, especially compared with an industry on 12.2x P/S.</li> <li>On the other hand, sceptics counter that the combination of a C¥78.0 million trailing 12 month loss and negative shareholders' equity helps explain why the discount exists, which means any bullish case rests on how investors weigh valuation against balance sheet strength.</li> </ul> </li> </ul> <p>Readers who want to see how different investors stitch these figures into a longer term story around revenue scale, loss trends, and risk often turn to a structured bull case to understand where the optimistic arguments start and end.<strong>🐂 Wuhan YZY Biopharma Bull Case</strong></p> <h2>Negative Equity And Volatile Share Price</h2> <ul> <li>The balance sheet currently carries negative shareholders' equity and the share price at HK$4.13 has been more volatile than the broader Hong Kong market over the last three months. Together these factors signal that both financial structure and trading behaviour carry added risk here.</li> <li>Those taking a more cautious stance argue that negative net assets and above market volatility sit uneasily alongside the ongoing trailing 12 month loss of C¥78.0 million, even though losses have narrowed by 17.6% per year over five years, because it leaves less room for error if results were to weaken again.     <ul> <li>Sceptics point to the combination of negative equity and recent higher volatility as clear markers that the company is operating with a thinner margin for setbacks than peers with positive net assets.</li> <li>At the same time, the history of loss reduction over several years and a trailing 12 month revenue base of C¥149.3 million mean the story is not simply about balance sheet pressure. This is why some investors still weigh the potential reward against the added risk.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Wuhan YZY Biopharma's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>Reading through all of this, do you feel the risks or the potential rewards stand out more right now? Use the data, act before sentiment shifts, and weigh up the 1 key reward and 2 important warning signs.</p> <h2>See What Else Is Out There</h2> <p>Wuhan YZY Biopharma is still posting sizeable losses alongside negative equity and higher share price volatility, which keeps the overall risk profile elevated for many investors.</p> <p>If that combination feels too uncomfortable right now, you may wish to shift your focus toward companies screened for stronger financial footing and lower risk by checking out 270 resilient stocks with low risk scores.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Wuhan YZY Biopharma might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

02496

<p>Wuhan YZY Biopharma (SEHK:2496) reported a revenue of C¥44.4 million and a basic EPS loss of C¥0.30 for 1H 2025, with a net loss of C¥58.8 million. Despite a revenue increase from C¥2.8 million in 1H 2024, the company continues to face significant losses. The current P/S ratio of 4.7x is below industry averages, indicating market skepticism about its profitability. While some investors see potential in the narrowing loss trend, concerns about negative equity and share price volatility persist, highlighting the risks involved in the company's financial outlook.</p>

Wuhan YZY Biopharma (SEHK:2496) Loss Deepens In 1H 2025 Challenging Improving Loss Trend Narrative